Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Change in the Management Team

Solwers Plc, Company Release, September 12, 2024, at 15:00 EEST Solwers Plc's Management Team Member, General Counsel and Board Secretary, Olli Kuusi, will be on parental leave starting from September 30, 2024, and continue his absence with a study leave until the end of 2025. The company will not hire a substitute for Kuusi but will utilize both external and internal existing resources during his absence. The company's Legal Counsel Sofia Korvenmäki will serve as the interim Board Secretary. _ For more information: Jasmine Jussila, Head of Group Communications, jasmine.

623 Competition Entries revealed for Finland’s New Museum of Architecture and Design in Helsinki

· The international open design competition attracted 623 entries from architect-led teams from around the world. · The open phase of the competition sought proposals for a building that will provide a home for Finland’s new national museum of architecture and design on a prominent and historic site on Helsinki’s South Harbour.  · Three to five designs will be selected for Stage 2 of the competition, receiving an award of €50,000 euros each. In addition, the jury will distribute three prize positions and two purchases totalling €150,000 at the end of the competition.

Sobi® and Enable Injections announce agreement to develop and distribute Aspaveli® in combination with enFuse® in Sobi territories

Sobi® (STO: SOBI) and Enable Injections, Inc. (Enable) today announced an international development and distribution agreement across Sobi territories for the enFuse® Injector, for the subcutaneous delivery of Aspaveli® (pegcetacoplan).     The enFuse Injector, to be produced by Enable and distributed by Sobi, is designed to streamline and improve patients’ self-administration experience with minimal disruption to their daily lives via the use of enFuse technology. This allows wearable, hidden needle drug delivery through a simple injection under the skin.   "We are dedicated to

Bong makes bond repurchase

Bong AB (publ) will make a repurchase of its own senior secured notes on the market. Bong has entered into purchase agreements with bondholders and the repurchase will be made on October 2[nd] to the nominal amount of SEK 23 million. The repurchase is related to the company’s own bond loan with an outstanding nominal amount before the repurchase of SEK 110 million which Bong issued in October 2021 with a 3 year tenure at the interest rate of Stibor (3m) +10 %. The senior secured notes are listed on Nasdaq Stockholm’s Corporate Bonds List with ISIN: SE0016829642. Bong is one of the

Immunovia carries out a directed issue of units to guarantors in connection with the completed rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.   LUND (SWEDEN) – The board of directors of Immunovia AB (publ) (”Immunovia” or ”the Company”), has today, based on the authorization granted by the annual general meeting on 19 June 2024, resolved on a directed issue of

Betsson announces the result of the voluntary tender offer and exercise right for early redemption of existing bonds 2022/2025

On 9 September 2024, Betsson AB (publ) (the “Company”) announced a tender offer to the holders of the Company’s existing senior unsecured bonds with ISIN SE0017769672 (the “Existing Bonds”) to participate in a tender offer where the Company, subject to the settlement of the bond issue which the Company announced on 9 September 2024 (the “New Bond Issue”), repurchases the Existing Bonds for cash at a price of 103.25 per cent. of the nominal amount plus accrued and unpaid interest (the “Tender Offer”). In accordance with the Company’s press release on 9 September 2024, the Tender Offer

Webstep ASA: Mandatory notification of trade

Oslo, 12 September 2024: Reference is made to the stock exchange announcement published by Webstep ASA (the "Company") on 29 August 2024, regarding a share lending agreement from Embro Eiendom AS, a closely related party to the Company's Chair of the Board, Kjell Magne Leirgulen, to DNB Markets, a part of DNB Bank ASA.The share lending agreement was entered into in order to facilitate the sale of a portion of new shares issued by the Company to option holders following the exercise of options under the Company's long-term incentive program. The shares lent out have today been returned.

Medivir to present mature clinical data for fostrox + Lenvima at ESMO Conference and to host a webcast on September 16

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, has previously announced that detailed and mature data from the phase 1b/2a study of fostrox (fostroxacitabine) in combination with Lenvima® (lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the European Society for Medical Oncology (ESMO) Congress in Barcelona, September 16, 2024.   The abstract, titled “Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with

Exel Composites launches a consultation process regarding its intention to close its factory in Belgium

EXEL COMPOSITES PLC               INSIDE INFORMATION                    12 SEPTEMBER 2024 AT 13:45 EESTExel Composites has completed the strategic review at its factory in Belgium initiated in January 2024. As a result, the company is entering into consultation with employee representatives regarding its intention to discontinue production at its Oudenaarde factory.   The consultation process concerns approximately 50 employees. The negotiations will be conducted and concluded in accordance with Belgian law, within the timeline necessary for due process.   “During this year, we

Danish offshore wind farms Vesterhav Nord and Vesterhav Syd inaugurated

Today, Danish Minister of Environment, Magnus Heunicke, Vattenfall’s Head of Wind Helene Biström and Country Manager for Vattenfall Denmark Anne Mette Traberg, officially inaugurated the two wind farms Vesterhav Nord and Vesterhav Syd. Combined, the winds farms are expected to generate an annual production of 1.5 TWh fossil-free electricity, equal the consumption of 350,000 households.The two, almost identical  wind farms, are located off the Danish west coast and consists in total of 41 wind turbines, each with a capacity of 8.4 MW. Both farms are entirely within Danish waters with the

Curasight A/S publishes prospectus due to upcoming rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Copenhagen, Denmark, 12 September 2024 – Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) announced on 4 September 2024 that the Board

Form 8.3 - Anglogold Ashanti Plc]

FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   +--------------------------------------------------------+---------------------+|(a) Full name of discloser: |Ninety One UK Ltd |+--------------------------------------------------------+---------------------+|(b) Owner or controller of interests and short positions|  ||disclosed, if different from 1(a):

Form 8.3 - Centamin Plc

FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   +--------------------------------------------------+---------------------------+|(a) Full name of discloser: |Ninety One UK Ltd |+--------------------------------------------------+---------------------------+|(b) Owner or controller of interests and short |  ||positions disclosed, if different from

Heart Aerospace Files Patent for Innovative Nacelle Integration Design, Improving Flight Characteristics of the ES-30

Heart Aerospace, the Swedish hybrid-electric airplane maker, has filed two EU design applications and one patent application for an innovative new nacelle integration design that significantly improves the flight characteristics of its regional hybrid-electric aircraft, the ES-30, allowing it to operate on shorter runways.In contrast to the most widespread designs, that locate the nacelle under the wing, Heart’s solution is centred on the wing and designed for a vortex generation at a high angle of attack (the angle between the wing and the oncoming airflow), preventing the nacelle from

Heart Aerospace Completes Ground Support Procedure Tests for Electric Aircraft

Swedish hybrid-electric airplane manufacturer Heart Aerospace, in collaboration with airlines Braathens Regional Airlines, SAS, and airport operator Swedavia completes ground support procedure tests for electric airplane in a push to bring more eco-friendly air travel closer to reality.The tests were conducted as part of the Swedish research project ELISE, which brings together technology companies with airlines and airports to foster the development of electric aviation infrastructure in Sweden. This phase of the ELISE project focused on creating a full-scale demonstrator of Heart’s

Navamedic announces an exclusive agreement with Alex Therapeutics for the development of a Companion App to aid in the treatment of Parkinson’s Disease

Stockholm Sweden, September 12, 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has partnered with Alex Therapeutics, a digital health provider of disease and drug companion apps, to aid in Parkinson’s treatment management. The app will be developed by Alex Therapeutics to support patients on Flexilev®, a prescription treatment for Parkinson’s disease.The new companion app provides medication management support that addresses the specific needs and challenges of people living with Parkinson’s disease. The

Alex Therapeutics has signed an exclusive agreement with Navamedic for the development of a Companion App to aid in the treatment of Parkinson’s Disease

Stockholm Sweden, September 12, 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has partnered with Alex Therapeutics, a digital health provider of disease and drug companion apps, to aid in Parkinson’s treatment management. The app will be developed by Alex Therapeutics to support patients on Flexilev®, a prescription treatment for Parkinson’s disease.   The new companion app provides medication management support that addresses the specific needs and challenges of people living with Parkinson’s

Heart Aerospace Unveils First Full-Scale Demonstrator for 30-seat Hybrid-Electric Airplane

Heart Aerospace, the Swedish hybrid-electric airplane maker, today unveils its first full-scale demonstrator airplane, marking a major milestone in the development of its regional hybrid-electric aircraft, the ES-30.Built almost entirely in-house at Heart’s Gothenburg facilities, the demonstrator reflects the company’s strategy to simultaneously develop both the design and production processes. “Our industry is approaching a 30-year innovation cycle, and we have less than 25 years to decarbonize aviation. We need to develop new methods to get net zero aerospace technologies to market

AirAsia Joins Heart Aerospace’s Industry Advisory Board to Shape the Future of Air Travel

Malaysia-based AirAsia, the fourth largest airline in Asia, has joined Heart Aerospace’s Industry Advisory Board to help shape the future of regional electric aviation. As a member of the board, AirAsia will provide strategic guidance and oversight on the design, development, and commercialisation of Heart Aerospace’s revolutionary hybrid-electric aircraft, the ES-30.The Industry Advisory Board consists of leading airlines, leasing companies, and airports worldwide—each representing critical components of the aviation ecosystem necessary to support the transformative shift toward electric

Lifestyle intervention from childhood to adolescence affects metabolism even years later

A new study from the University of Eastern Finland (UEF) uncovers how early lifestyle changes can have long-lasting impacts. A diet and physical activity intervention in childhood and adolescence was found to profoundly influence metabolism even years later. The Physical Activity and Nutrition in Children (PANIC) study is the first lifestyle intervention study using advanced liquid chromatography-mass spectrometry (LC-MS) metabolomics technology to analyse molecular mechanisms underlying the health effects of lifestyle changes from childhood to adolescence. By analysing blood samples,

Clas Ohlson expands in Tønsberg, Norway

Clas Ohlson's new store in Tønsberg, Norway, opened this morning. The store is Clas Ohlson's second store in the city."We have been a  popular destination in Tønsberg ever since we established our first store in the city 23 years ago. We are very happy to be able to grow in Tønsberg and become even more accessible," says Rune Johansen, Country Operations Manager. The new Clas Ohlson store is located in the newly built  Kilen Handelspark, just outside Tønsberg city centre. The first phase of the retail park was opened in June this year, and now the second phase has been completed,

Veidekke: New housing commission in Sandnes

Veidekke has been commissioned by K2 Bolig and Bane NOR Eiendom to erect the first stage of the Skeiane station residential project in Stavanger. The contract comprises includes 47 apartments, common rooms, guest bedsits, a separate parking and bicycle garage and commercial premises. This will be a design and build contract valued at close to NOK 100 million, excluding VAT.“We are very pleased to have won the competition for this commission and to have gained renewed trust from a good customer in K2 Bolig and Bane NOR Eiendom. This is a great project with good qualities and a nice location

Eidra acquires Wipfli's Product Studio and expands in the US market

Eidra is expanding in the US market with the acquisition of Wipfli's Product Studio business and revives the Punchkick brand. This strategic acquisition marks a significant milestone in Eidra's mission to drive positive change through the seamless fusion of strategy, design, and technology.Eidra and Punchkick have a shared vision for the future and are dedicated to pushing the boundaries of what is possible in the digital space. By combining strengths, they can offer a comprehensive suite of services that includes strategy, design, development, and implementation. Clients can expect a

BioStock: Final study results - ColdZyme reduces illness duration and alleviates symptoms

An independent investigator-initiated study from the University of Kent demonstrates that Enzymatica’s mouth spray ColdZyme reduces the duration of upper respiratory tract infections by up to five days in endurance athletes, enabling faster return to training. Additionally, ColdZyme alleviates symptoms and decreases the viral load of rhinovirus, the most common cause of a cold. Principal investigator Glen Davison shared insights on these results in an interview with BioStock.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/final-study-

There are no items matching the current filter
There are no more items matching the current filter
Back to top